Mode
Text Size
Log in / Sign up
N/A N=300 Randomized Triple-blind Prevention

Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation

Immune System and Related Disorders

Enrolled (actual)
300
Serious AEs
0.0%
Results posted
Nov 2020
Primary outcome: Primary: Level of Pain — .39; .19; .14; .56 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Ibuprofen (Drug); Compound Exercise of Push-ups (Behavioral); oral placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Womack Army Medical Center
Primary completion
Dec 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Level of Pain
.39; .19; .14; .56; .22; .19
SECONDARY
Serologic Response - A/California/7/2009
216.75; 171.00; 214.80; 343.03; 239.25; 345.09
SECONDARY
Serologic Response - A/Hong Kong / 4801/2014
221.09; 177.78; 149.22; 296.66; 243.13; 232.58
SECONDARY
Serologic Response - B/Phuket/3073/2013
36.69; 40.16; 32.89; 44.78; 47.34; 49.07
SECONDARY
Serologic Response - B/Brisbane/60/2008
26.09; 17.41; 26.00; 34.09; 25.47; 41.02
SECONDARY
Participants With Erythema
0; 0; 0
SECONDARY
Participants With Edema
0; 0; 0

Summary

The purpose of this clinical investigation is to evaluate the efficacy and immunologic effects of a non-pharmacological exercise intervention (push-ups) compared to an oral NSAID (ibuprofen) and an oral placebo to decrease local injection site inflammation symptoms of delayed pain, erythema, and edema and any impact on serologic antibody immune response after influenza vaccine receipt.

Eligibility Criteria

Inclusion Criteria

Must:

  • Be Active Duty Service Members.
  • at least 18 years of age or older.
  • Be requiring and eligible for inactivated influenza vaccine receipt.
  • Be willing and able to complete the study protocol requirements.
  • Have a current Flu Screening Form with medical clearance to receive the influenza vaccination.

Exclusion Criteria

Must Not:

  • Have already received influenza vaccine for the current season.
  • Have received any type of vaccine in the previous 72 hours.
  • Be on a medical profile resulting in current profile exemption from Physical Training of Upper 2 or Upper 3. (Upper extremity injury or illness)
  • Have preexisting symptoms of injury or infection or other local symptoms that would interfere with site assessment.
  • Be pregnant.
  • Have a history of allergy, intolerance, stomach bleeding or other medical exclusion for ibuprofen.
  • Have a history of stroke or coronary artery disease, such as uncontrolled high blood pressure or abnormal heart beat.
  • Has taken any topical or oral pain medications from the following medication classes in the past 24 hours prior to the start of the study: oral acetaminophen, opioids, tramadol, nonsteroidal anti-inflammatory drug (NSAID) or acetylsalicylic acid (ASA) or topical pain relievers or counterirritants of menthol, methyl salicylate, camphor menthols, and capsaicins.
  • Have any chronic or acute illness or treatment causing immunological suppression such as current oral steroid therapy, malignancy or chemotherapy or lung disease. (not including controlled asthma)
  • Currently participating in any other study

-

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02807623). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search